Pipeline

ATP128

Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of colorectal cancer.

Colorectal cancer is a leading cause of mortality and provides a significant market opportunity ($11 billion by 2025) for us with few cancer vaccine competitors.

This target is well suited for the self-adjuvanting KISIMA^® immunisation platform which is able to turn a cold tumour into a hot tumour in this programme, promoting the tumour infiltration by immune cells.

ATP128 has entered phase I clinical trials in 2019.